Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds

Current Cancer Drug Targets

Volumn 11, Issue 8, 2011, Pages 919-928

  Blanquart, C ^a   Francois M ^a   Charrier, C ^b   Bertrand, P ^b   Gregoire, M ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

BRET; Cancer; HDAC; Histones; Inhibitors; Pharmacology

Indexed keywords

4 METHYL 5 (2 METHYL 3 OXO 2,3 DIHYDROBENZOFURAN 2 YL)PENTA 2,4 DIENOIC ACID BENZAMIDE; 4 METHYL 5 (2 METHYL 3 OXO 2,3 DIHYDROBENZOFURAN 2 YL)PENTA 2,4 DIENOIC ACID HYDROXAMIDE; 5 (6 DIMETHYLAMINO 2 METHYL 3 OXO 2,3 DIHYDROBENZOFURAN 2 YL) 4 METHYL PENTA 2,4 DIENOIC ACID BENZAMIDE; 5 (6 DIMETHYLAMINO 2 METHYL 3 OXO 2,3 DIHYDROBENZOFURAN 2 YL) 4 METHYL PENTA 2,4 DIENOIC ACID HYDROXAMIDE; BENZOFURAN DERIVATIVE; HISTONE; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DNA METHYLATION; DRUG SCREENING; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; REPRODUCIBILITY; TECHNOLOGY;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; KINETICS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RATS; RECOMBINANT FUSION PROTEINS;

EID: 80052824539     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911797264761     Document Type: Article

References (31)

1. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27 (32), 5459-5468.
2. Xu, Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 2003, 10 (4), 400-403.
3. Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18 (5), 601-607.
4. Martinet, N.; Bertrand, P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag. Res. 2011, 3 117-141.
5. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5 (9), 769-784.
6. Vrana, J. A.; Decker, R. H.; Johnson, C. R.; Wang, Z.; Jarvis, W. D.; Richon, V. M.; Ehinger, M.; Fisher, P. B.; Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18 (50), 7016-7025.
7. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (18), 10014-10019.
8. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E. T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (44), 16090-16095.
9. Kumagai, T.; Wakimoto, N.; Yin, D.; Gery, S.; Kawamata, N.; Takai, N.; Komatsu, N.; Chumakov, A.; Imai, Y.; Koeffler, H. P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 2007, 121 (3), 656-665.
10. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R. L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3 5.
11. Duvic, M.; Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 2007, 16 (7), 1111-1120.
12. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R. W.; Gardner, E. R.; Figg, W. D.; Bates, S. E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 2010, 10 (7), 997-1008.
13. Charrier, C.; Clarhaut, J.; Gesson, J. P.; Estiu, G.; Wiest, O.; Roche, J.; Bertrand, P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J. Med. Chem. 2009, 52 (9), 3112-3115.
14. Xu, Y.; Piston, D. W.; Johnson, C. H. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (1), 151-156.
15. Angers, S.; Salahpour, A.; Joly, E.; Hilairet, S.; Chelsky, D.; Dennis, M.; Bouvier, M. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (7), 3684-3689.
16. Ayoub, M. A.; Couturier, C.; Lucas-Meunier, E.; Angers, S.; Fossier, P.; Bouvier, M.; Jockers, R. Monitoring of ligandindependent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 2002, 277 (24), 21522-21528.
17. Boute, N.; Pernet, K.; Issad, T. Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol. Pharmacol. 2001, 60 (4), 640-645.
18. Blanquart, C.; Boute, N.; Lacasa, D.; Issad, T. Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer. Mol. Pharmacol. 2005, 68 (3), 885-894.
19. Issad, T.; Blanquart, C.; Gonzalez-Yanes, C. The use of bioluminescence resonance energy transfer for the study of therapeutic targets: application to tyrosine kinase receptors. Expert Opin. Ther. Targets 2007, 11 (4), 541-556.
20. Kanno, T.; Kanno, Y.; Siegel, R. M.; Jang, M. K.; Lenardo, M. J.; Ozato, K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 2004, 13 (1), 33-43.
21. Sasaki, K.; Ito, T.; Nishino, N.; Khochbin, S.; Yoshida, M. Realtime imaging of histone H4 hyperacetylation in living cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (38), 16257-16262.
22. Bacart, J.; Corbel, C.; Jockers, R.; Bach, S.; Couturier, C. The BRET technology and its application to screening assays. Biotechnol. J. 2008, 3 (3), 311-324.
23. Dhalluin, C.; Carlson, J. E.; Zeng, L.; He, C.; Aggarwal, A. K.; Zhou, M. M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399 (6735), 491-496.
24. Jacobson, R. H.; Ladurner, A. G.; King, D. S.; Tjian, R. Structure and function of a human TAFII250 double bromodomain module. Science 2000, 288 (5470), 1422-1425.
25. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409 (2), 581-589.
26. Rocca, A.; Minucci, S.; Tosti, G.; Croci, D.; Contegno, F.; Ballarini, M.; Nole, F.; Munzone, E.; Salmaggi, A.; Goldhirsch, A.; Pelicci, P. G.; Testori, A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 2009, 100 (1), 28-36.
27. Li, Q.; Zhou, H.; Wurtele, H.; Davies, B.; Horazdovsky, B.; Verreault, A.; Zhang, Z. Acetylation of histone H3 lysine 56 regulates replication-coupled nucleosome assembly. Cell 2008, 134 (2), 244-255.
28. Chen, C. C.; Carson, J. J.; Feser, J.; Tamburini, B.; Zabaronick, S.; Linger, J.; Tyler, J. K. Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair. Cell 2008, 134 (2), 231-243.
29. Morris, S. A.; Rao, B.; Garcia, B. A.; Hake, S. B.; Diaz, R. L.; Shabanowitz, J.; Hunt, D. F.; Allis, C. D.; Lieb, J. D.; Strahl, B. D. Identification of histone H3 lysine 36 acetylation as a highly conserved histone modification. J. Biol. Chem. 2007, 282 (10), 7632-7640.
30. Daud, A. I.; Dawson, J.; DeConti, R. C.; Bicaku, E.; Marchion, D.; Bastien, S.; Hausheer, F. A., 3rd; Lush, R.; Neuger, A.; Sullivan, D. M.; Munster, P. N. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin. Cancer Res. 2009, 15 (7), 2479-2487.
31. Munster, P. N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J. H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101 (7), 1044-1050.